Pfizer Inc

NYSE: PFE
$27.41
+$0.05 (+0.2%)
Real Time Data Delayed 15 Min.

PFE Articles

Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Friday's top analyst upgrades and downgrades included American Airlines, Chipotle Mexican Grill, Ericsson, Microsoft, Mylan, Novavax, Pfizer, Procter & Gamble, Qualcomm, Square and Starbucks.
BioNTech stock jumped on Tuesday and went even higher early on Wednesday. This comes after the company announced a collaboration with the pharmaceutical giant Pfizer.
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Pfizer, Intel and Exxon above all other Dow stocks.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Pfizer, Microsoft and Intel above all other Dow stocks.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Pfizer, Microsoft and Intel above all other Dow stocks.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive, Pfizer, Valero Energy and...
Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin out part of its operations. Executing this effort may create some operational uncertainty inside of...
Pfizer stock retreated after it released a disappointing fourth-quarter earnings report before the opening bell Tuesday.
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Microsoft, Pfizer and Intel above all other Dow stocks.